BR112022005224A2 - Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais - Google Patents

Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais

Info

Publication number
BR112022005224A2
BR112022005224A2 BR112022005224A BR112022005224A BR112022005224A2 BR 112022005224 A2 BR112022005224 A2 BR 112022005224A2 BR 112022005224 A BR112022005224 A BR 112022005224A BR 112022005224 A BR112022005224 A BR 112022005224A BR 112022005224 A2 BR112022005224 A2 BR 112022005224A2
Authority
BR
Brazil
Prior art keywords
fgfr
inhibitors
genetically altered
cancers
immune checkpoint
Prior art date
Application number
BR112022005224A
Other languages
English (en)
Inventor
Elena Santiago-Walker Ademi
Enrique Zudaire
Raluca Verona
S Shalaby Waleed
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022005224A2 publication Critical patent/BR112022005224A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais. a presente invenção refere-se a um método de tratar câncer em um paciente compreendendo administrar um inibidor de ponto de verificação ao paciente, em que o paciente foi diagnosticado com um câncer geneticamente alterado por fgfr e foi pré-tratado com um inibidor de fgfr, tal como erdafitinibe.
BR112022005224A 2019-09-26 2020-09-25 Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais BR112022005224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906517P 2019-09-26 2019-09-26
PCT/EP2020/076999 WO2021058798A1 (en) 2019-09-26 2020-09-25 Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings

Publications (1)

Publication Number Publication Date
BR112022005224A2 true BR112022005224A2 (pt) 2022-06-14

Family

ID=72665262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005224A BR112022005224A2 (pt) 2019-09-26 2020-09-25 Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais

Country Status (12)

Country Link
US (1) US20220348662A1 (pt)
EP (1) EP4034118A1 (pt)
JP (1) JP2022550110A (pt)
KR (1) KR20220070243A (pt)
CN (1) CN114466662A (pt)
AU (1) AU2020352668A1 (pt)
BR (1) BR112022005224A2 (pt)
CA (1) CA3151395A1 (pt)
IL (1) IL291594A (pt)
JO (1) JOP20220073A1 (pt)
MX (1) MX2022003686A (pt)
WO (1) WO2021058798A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023044119A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Lymphatic fluid for diagnostics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US20160090633A1 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
BR112017017700A2 (pt) * 2015-02-19 2018-07-31 Bioclin Therapeutics Inc métodos, composições e kits para tratamento do câncer
TWI791422B (zh) * 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合

Also Published As

Publication number Publication date
IL291594A (en) 2022-05-01
MX2022003686A (es) 2022-04-25
WO2021058798A1 (en) 2021-04-01
EP4034118A1 (en) 2022-08-03
CN114466662A (zh) 2022-05-10
JOP20220073A1 (ar) 2023-01-30
JP2022550110A (ja) 2022-11-30
CA3151395A1 (en) 2021-04-01
AU2020352668A1 (en) 2022-03-31
US20220348662A1 (en) 2022-11-03
KR20220070243A (ko) 2022-05-30

Similar Documents

Publication Publication Date Title
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112017018234A2 (pt) inibidores de pd-1 / pd-l1 para o tratamento de câncer
MX2017003227A (es) Terapias de combinacion de inhibidores de alk.
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2019013862A (es) Terapia de combinacion.
DOP2019000019A (es) Metodos para tratar el cancer de prostata
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CO2022000481A2 (es) Inhibidores de enzimas
MX2020001727A (es) Terapia de combinacion.
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112022005224A2 (pt) Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
AU2017245414A1 (en) The cure for cancer
BR112018069174A2 (pt) tratamento de prurido urêmico